Objective: Although many HIV-infected (HIVþ) and HIV-exposed but uninfected (HEU) infants have received live rotavirus vaccines since the WHO recommended universal administration of these vaccines to infants, there has been limited prospective information on their safety and immunogenicity in either group of infants. Design/methods: We performed a randomized, double-blinded, placebo-controlled trial of the safety and immunogenicity of oral pentavalent rotavirus vaccine (RV5) administered to HIVþ and HEU infants in four African countries. Ninety-three percent of HIVþ infants were receiving antiretroviral therapy prior to vaccination. Participants were followed for safety. Immune responses were measured 14 days after three doses of RV5, including serum antirotavirus neutralizing and IgA antibodies, IgA antibody in stool, and antirotavirus memory B and T-cell FluoroSpot. Shedding of RV5 in stool was monitored.
Introduction
Rotavirus is a major cause of infant diarrheal morbidity and mortality worldwide [1, 2] . Live attenuated rotavirus vaccines reduce rotavirus-related disease in healthy children in resource-rich and resource-limited countries [3] [4] [5] . Diarrheal disease is a major cause of sickness and death in HIV-infected (HIVþ) children; some studies report that rotavirus infection is more severe in HIVþ children [5] [6] [7] [8] [9] . Although many HIVþ infants have received live rotavirus vaccines since the WHO recommendation for these vaccines, the efficacy of rotavirus vaccines for HIVþ infants has not been determined [10] [11] [12] . Information on the safety and immunogenicity of rotavirus vaccines in HIVþ infants is limited to approximately 100 infants who received the monovalent rotavirus vaccine (Rotarix, GlaxoSmithKline, Research Triangle Park, North Carolina, USA; RV1) [12, 13] , and less than 50 infants who received the pentavalent rotavirus vaccine (RotaTeq, Merck & Co., Inc.; RV5) [14, 15] . Additional information about rotavirus vaccines in HIVþ infants is desirable because protective antibody responses can be impaired in infants with untreated HIV infection [16] [17] [18] [19] , and robust responses may not be achieved even when vaccine is administered after initiating antiretroviral therapy (ART) early in life [18, [20] [21] [22] . This may be more problematic in resource-poor countries where rotavirus vaccines induce lower titers of rotavirus-specific antibody and vaccine efficacy is lower than in resource-rich countries [23] . Moreover, although HIVþ infants may benefit from rotavirus vaccines, these vaccines have been implicated in prolonged gastroenteritis with persistent shedding of vaccine-strain virus in infants with severe immune deficiency, and other live viral vaccines have caused disease in children with advanced HIV infection [24] [25] [26] [27] . Information about rotavirus vaccination of infants who are HIV exposed but uninfected (HEU) is also desirable, as HEU infants have an excess of infectious morbidity during the first year of life [28, 29] . Although HEU infants make normal levels of antibody to some vaccines typically administered during infancy [30] , information on the immunogenicity and safety after administration of rotavirus vaccines to HEU infants is important, given the large number of infants born to HIVþ women.
The current report describes a randomized, placebocontrolled trial comparing the safety and immunogenicity of RV5 in HIVþ and HEU infants.
Methods

Study design
The study (P1072) sponsored by the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) network was a phase II, randomized, double-blind study of RV5 in infants born to HIVþ mothers (NCT00880698). It was approved by Institutional Review Boards of IMPAACT and appropriate institutions or national governments. Parental consent was obtained. P1072 was conducted in four African countries where rotavirus vaccine was not in the national vaccination program. Infants between 2 and less than 15 weeks old at screening were determined to be HEU or in one of three HIVþ strata (details in Supplemental Information, http://links.lww.com/ QAD/A980). Infants in each stratum were randomized to receive RV5 or placebo: study dose 1 at 4 to less than 15 weeks, and study doses 2 and 3 at least 28 days after the previous vaccination, with dose 3 by 32 weeks or less. Participants were followed until 6 weeks after the last dose, with visits at 7, 14, 21, and 42 days after each dose to record clinical signs, symptoms, and new significant diagnoses. No clinical laboratory testing was required, but sites recorded laboratory results considered pertinent. Stool samples were collected at entry; at days 7, 14, 21, and 42 after dose 1; at days 7 and 21 after doses 2 and 3; and at unplanned visits for gastroenteritis. Blood for immunogenicity testing was collected at entry and 14 days after dose 3 (42 days if not collected at 14 days).
Study conduct
Shortly after the study began, the protocol was amended to require HIVþ infants to receive ART before receiving study vaccine. Six of 76 (7%) of these infants received study vaccine prior to this requirement. Enrollment was closed in participating countries when RV1 was added to national vaccine schedules (details in Supplemental Information, http://links.lww.com/QAD/A980).
Study outcomes
Safety Laboratory values, signs, symptoms, and diagnoses were graded according to the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events [31] . Sites reported grade !1 signs, symptoms, and diagnoses. Events that were grade !2, and grade !1 targeted signs/symptoms (vomiting, fever, diarrhea, irritability), targeted diagnoses (gastroenteritis, intussusception, and diagnoses with the rotavirus organism code), and deaths were reviewed by the Core Team [study chairs, immunologist, National Institutes of Health (NIH) medical officers, and pharmaceutical representatives].
Immunogenicity
Serum antirotavirus neutralizing antibodies (SNAs):
Neutralizing antibodies to type-specific outer surface proteins of RV5 (G1, G2, G3, G4, and P1A) were measured as published [32] (details in Supplemental Information, http://links.lww.com/QAD/A980).
Serum antirotavirus IgA antibody was measured by a standard enzyme immunoassay (EIA) format previously published [33] (details in Supplemental Information, http://links.lww.com/QAD/A980).
Coproantibody (stool antirotavirus IgA) was measured in stool filtrates by the methods used for serum IgA, but standardized to total IgA and reported as rotavirus antigen units per microgram of total IgA.
Antirotavirus memory B and T-cell responses (FluoroSpot)
Memory B-cell responses Peripheral blood mononuclear cells were cryopreserved at clinical sites using a standardized protocol [34] , and shipped for detection of IgG/IgA secreting cells (details in Supplemental Information, http://links.lww.com/ QAD/A980).
T-cell responses
A dual color IFNg and IL-2 ELISPOT assay (ELISPOT, FluoroSpot kit; MabTech, Nacka Strand, Sweden) was used per manufacturer's instructions (details in Supplemental Information, http://links.lww.com/QAD/A980).
Shedding of rotavirus in stool: Rotavirus in stool was initially assessed using an ELISA assay using a published commercial rotavirus antigen detection kit [35] . Positive samples were identified as vaccine or wild type with reverse transcriptase-polymerase chain reaction (RT-PCR) assays specific for rotavirus VP4, VP6, and VP7 genotypes, and infectious virus identified with a fluorescent focus assay (FFA) [35] .
Statistical methods
Baseline and safety data were presented 'as randomized' (intent-to-treat). Immunogenicity analyses were conducted in the 'per-protocol' population, defined as participants completing the three as-randomized vaccinations within the required windows. Sensitivity analyses were done for safety, only including participants who received the correct vaccine, and for immunogenicity, in the intent-to-treat population. Proportions were presented with exact 95% confidence intervals and compared using Fisher's exact tests (unadjusted) and logistic regression (adjusted). Continuous outcomes were compared using Wilcoxon rank sum tests (unadjusted) and censored normal regression on log 10 -transformed levels adjusted for other covariates.
Safety
Proportions of participants experiencing new adverse events (appearing after the first vaccination, or increased grade reported after the first vaccination) were presented by HIV-1 stratum and vaccine group.
Immunogenicity
Serum antibodies Measurements outside the lower limit of quantitation (LLOQ) or upper limit of quantitation of each assay were set to those limits. The primary outcome measure was predefined as at least three-fold increase achieved postdose 3 (PD3) in SNA and IgA over the entry value. If the entry value was above one-third of the upper limit of quantitation, the infant was not classified as a responder and was excluded from analysis. The secondary outcome was antibody level PD3.
B and T-cell responses
IgA and IgG memory B cells were measured in samples from a randomly chosen subset that received three vaccinations and met viability assay criteria. Each response was measured in duplicate wells at entry, 14, and 42 days PD3. If two measurements were available, the analysis unit was the mean of both responses. T-cell responses were calculated as the difference between WC3-containing wells and the MA104 controls. Negative differences and differences of zero were set to 0.1 to allow log transformation for analysis. Participants were classified as responders if they achieved at least twofold increase over entry levels by either 14 or 42 days PD3.
Coproantibodies: Measurements below the LLOQ were set to the LLOQ. Spearman correlations were calculated on PD3 levels of coproantibodies and serum IgA antibodies.
Vaccine virus in stool: Numbers of infants with EIApositive stool after each study dose were reported. The EIA-positive samples that were FFAþ and RT-PCRþ for VP6 were summarized.
Analyses were conducted in Statistical Analysis System Version 9.4; SAS Institute Inc., Cary, North Carolina, USA). 
Results
Accrual and baseline characteristics
Safety
Adverse events and targeted signs/symptoms are summarized in Table 2 . Proportions of participants with adverse events tended to be higher in HIVþ infants, but this was true regardless of exposure to RV5. There was no statistically significant difference in proportions of HIVþ or HEU participants receiving either RV5 or placebo, or within CD4% strata for the HIVþ infants ( Table 2;  Supplemental Tables 1 and 2 , http://links.lww.com/ QAD/A980). Event rates within 7 days of vaccination were similar. CD4% increased and HIV RNA viral load decreased significantly in HIVþ infants from entry to study end in both RV5 and placebo recipients, with no differences in the magnitude of change in CD4% or proportions of participants with HIV-1 RNA 400 copies/ ml or less between vaccine groups.
Three HIVþ infants (one RV5, two placebo) died of pneumonia 3-4 weeks after the first study dose. These were deemed by the site and Core Team as not, or probably not, related to study vaccine. Eight HIVþ infants (five RV5, three placebo) and five HEU infants (two RV5, three placebo) were hospitalized during the study. Reasons for hospitalization were gastroenteritis (4), pneumonia (4), malaria (1), measles (1), febrile seizures (1), and no diagnosis recorded (2) . There were no statistically significant differences between RV5 and placebo in changes from baseline in WHO weight or height-for-age z-scores. HIV test results were available for 121/126 HEU infants at least 14 days PD3; all were negative. Six infants were not on ARVs when they received the first study vaccination.
Rotavirus serum antibody responses
The proportion of antirotavirus IgA responders (at least three-fold increase from baseline) reached 81% in both HIVþand HEU recipients of RV5 and was approximately 2.5 to three-fold higher than in placebo recipients (Table 3) . Response rates in the SNA assay varied by serotype ($20-60%). Proportions of RV5 recipients responding to each serotype was consistently higher, for both HIVþ and HEU infants, compared with placebo recipients. For all SNA assays except P1A, the proportion of RV5 responders was higher in HIVþ compared with HEU infants. This was likely because of higher levels of transplacentally transferred maternal antibodies in HEU infants, which limited their ability to achieve a three-fold increase in SNA antibody after vaccination. This is demonstrated in Table 4 and Supplemental Figure 2 , http://links.lww.com/QAD/A980, which show that median levels for each specific antibody were higher in the HEU infants at baseline (P 0.001 for all SNA). Antibody levels were consistently higher in RV5 recipients, for both HIVþ and HEU infants compared with placebo recipients. Importantly, both IgA and SNA postvaccination antibody levels were not significantly different by HIV status (Table 4 and Supplemental Figure  2 , http://links.lww.com/QAD/A980).
Adjusted analyses were performed to identify potential predictors of response and of levels achieved PD3 among RV5 recipients. Covariates included infant ever breastfed, oral polio vaccine coadministered with the first or with three vaccinations, infant exposure to prophylaxis to prevent PMTCT, and any detection of rotavirus antigen in stool between the first and last doses. For HIVþ infants, additional covariates included screening CD4%, entry HIV-1 RNA, infant exposure to PMTCT, and number of days on ART at entry. Adjusted analyses for each of these factors had little effect on the magnitude or statistical significance of the odds of responding to RV5 relative to estimates from unadjusted models (data not shown). No covariates were consistently associated with the odds of responding or with PD3 levels across immunologic assays. Because of the number of models fit and the lack of consistent findings across outcomes, we do not report the few statistically significant findings.
Rotavirus coproantibodies
Median (Q1, Q3) levels of coproantibodies at entry were higher in HIVþ than in HEU infants, but the difference was not statistically significant (P ¼ 0.13; Table 4 ). Postvaccination levels were significantly higher in RV5 recipients compared with placebo recipients in HEU, but not HIVþ infants. Coproantibody levels were not significantly different in RV5 recipients between the HIVþ and HEU infants. Coproantibody and serum antibody levels PD3 were positively correlated [Spearman RV5 in HIV-exposed African infants Levin et al. 53 
Cellular immunity
At entry, rotavirus-specific B and T-cell immunity were very low (median ¼ 0.1; Table 5 ) and did not differ by HIV status. After vaccination, IgA B-cell memory was significantly higher in HIVþ infants receiving RV5 compared with placebo recipients (P ¼ 0.04; Table 5 ), although this was based on the distribution of values in the third quartile and the magnitude of the difference was small. There were no significant differences in HEU infants. IgG memory B-cell responses did not appreciably increase after vaccination. There were no statistically significant differences in proportions of participants with at least two-fold increase in WC3-specific memory B or T cells at PD3 compared with entry, either by vaccine group within HIV status or by HIV status in RV5 recipients (Table 5) . These results should be interpreted with caution, because at entry, most participants had no secreting T or B cells, so that small increases were considered a response. PHA responses were poor and did not differ between vaccine groups or by HIV status in RV5 recipients (data not shown).
Fecal shedding
All participants had at least one stool sample collected after the first vaccination (Supplemental Table 3 , http:// links.lww.com/QAD/A980). Nine of 99 (9%) RV5 recipients after the first dose, and one of 98 after the second dose, had at least one stool sample positive for rotavirus by EIA. Across all samples at all times, rotavirus was detected by EIA in 13.0% (eight of 62; one positive after both dose 1 and 2) of the HEU infants and in 2.7%
(one of 37) of the HIVþ infants who received RV5; for placebo recipients, these percentages were 6.3% (four of 64) for the HEU and 7.7% (three of 39) for the HIVþ infants.
All EIA-positive samples were evaluated by FFA to determine if infectious rotavirus was present, and by RT-PCR to determine the rotavirus source, and were further characterized by VP4 and VP7 type. Only one of 37 (2.7%) HIVþ RV5 recipients shed FFAþ vaccine-type rotavirus after the first vaccination. No shedding was detected in any infant after the third vaccination.
Discussion
There was no evidence that RV5 was associated with excess adverse signs or symptoms in either HIVþor HEU infants. Two of three deaths in HIVþ infants occurred in placebo recipients. One death and eight hospitalizations occurring in HIVþ infants were attributed to infectious causes common in these infants. Moreover, vaccination did not alter the CD4% or viral load response to ART in RV5 recipients during the study. Although limited in number, no HEU recipients of RV5 acquired HIV infection during the study. The prospective safety information collected is reassuring and consistent with previously published information for both rotavirus vaccines.
Virus-specific serum IgA antibody responses after RV5 vaccination were not significantly different in HIVþ and HEU infants, both in terms of three-fold rise and postvaccination titer. Of note, levels of serum IgA, which is not transplacentally transferred, did not differ before vaccination between HEU and HIVþ participants. This is important because serum IgA has been associated with protection against symptomatic disease and disease severity after natural exposure [36] [37] [38] [39] , and serum IgA correlated with protection in a study of an experimental rhesus rotavirus vaccine [33] . The magnitude of IgA antibody induced by RV5 in the current study was almost identical, utilizing the same laboratory assay, to that reported in a large trial of the safety and efficacy of RV5 in Africa [15] . A systematic review of rotavirus vaccine trials in settings stratified by rate of childhood mortality (as a marker for medical and other resources) found that postvaccination IgA antibody titer was lower in countries with higher childhood mortality and that titer correlated with lower efficacy [40] . In this context, our data suggest that the efficacy of the RV5 vaccine will not only be lower in HIVþ or HEU compared with HIV-unexposed African infants, but also not as high as in infants in the United States.
Coproantibodies were significantly induced by RV5 in HEU infants only, although there were no significant differences in PD3 levels between HIVþ and HEU infants after RV5 administration. The correlation of coproantibodies with protection is less clear in adult challenge models and in relation to natural infection [41, 42] .
The assessment of SNA responses also demonstrated an increase in virus-specific antibody levels after RV5. These differed by antigen and were especially strong against G1 and G4. Variable response by antigen was previously reported from the US and African efficacy studies, where G1 and G4 seroresponses were also most prominent [15, 43] . SNA levels PD3 in RV5 recipients were not statistically different between HIVþ and HEU infants. SNA levels have also been associated with protection in clinical trials, including an analysis of 1857 study participants in phase II/III trials of RV5 that correlated titers of SNA against G1 with protection against rotavirus gastroenteritis [41, 44] . Most vaccinees were breastfed (63%) and most received oral polio vaccine (75% for dose 1, 59% for dose 2) concomitant with RV5. With the caveat of the limited sample size, we did not find that either of these interfered with the immune response to RV5, which is consistent with the published literature [45, 46] . In addition, there was no discernible effect of entry CD4% or viral load on antibody responses. This is the first study of an orally administered live vaccine to HIVþ infants that stipulated ART prior to immunization. At the time of the first dose of RV5, 92% of the 37 HIVþ infants were receiving ART and only one had a CD4% less than 15. These were likely important factors in the responses to RV5, which significantly increased three different types of antibody utilizing three different laboratory methods. The second and third RV5 doses were administered after an interval of at least 1 and 2 months, respectively, of beginning ART, which may have contributed to the similar responses in both HIVþ and HEU infants. Moreover, where comparisons can be made, antibody titers after RV5 were similar to those reported in prior trials in unexposed and uninfected infants [15, 43, 44] . The paucity of shedding of RV5 after vaccination is additional evidence of immune preservation in our study participants.
HIVþ and HEU infants responded equally in all three immune assays. HEU infants were considered an appropriate proxy for healthy children, as the effectiveness of RV1 was the same in HEU and HIV-unexposed infants in a prior study [12] . However, the data on the adequacy of the HEU responses to vaccines is still mixed [30, 47] . In the past, responses reported after childhood vaccinations were impaired in HIVþ infants, especially in those with low CD4%, high HIV viral load, and short duration of ART [17, 19] . This is why current recommendations are to reimmunize HIVþ children who had been immunized before HIV therapy, but to delay this until 3 months after beginning ART [47, 48] . This would not be feasible for rotavirus vaccines because of the need to provide protection early in infancy. The current study suggests that very early administration of rotavirus vaccines may be effective when given concomitant with ART. Furthermore, considering that in this study most infants received study vaccine at 80-90 days of life, and that they had only been on ART for a median of 4 days, the outcome measures might have been even better if ART was started earlier.
There is also evidence that the magnitude and duration of immune memory is impaired when immunization is attempted in severely immune suppressed HIVþ children, and that immune memory may be preserved when ART is started in infancy [47, 49] rotavirus infection [50] . Whether RV5 establishes persistent memory is an important question, as protection into the second year of life is essential, especially in resource-poor countries. Assuming that ART is started shortly after birth in HIVþ infants, as in this study, the third dose will be given after a long period of ART. This might influence persistence, as suggested by a report that a third dose of RV1, compared with the recommended two doses for that vaccine, resulted in higher serum IgA titers and significantly greater efficacy in the second year postvaccination in a developing world setting [51, 52] .
The relatively small sample size of this study and the absence of an HIV-unexposed control group limit our ability to make definitive statements about RV5 in HIVþ infants. Nevertheless, we found RV5 to be immunogenic in this placebo-controlled, randomized clinical trial and no safety signal was apparent. In the future, accurate assessment of the safety and value of rotavirus vaccines in HEU and HIVþ infants will require larger-scale effectiveness studies, as performing placebo-controlled efficacy trials will no longer be ethical.
